Sun Pharm Inds Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SUN PHARM INDS INC, and when can generic versions of SUN PHARM INDS INC drugs launch?
SUN PHARM INDS INC has ninety-seven approved drugs.
There are eleven US patents protecting SUN PHARM INDS INC drugs. There are two tentative approvals on SUN PHARM INDS INC drugs.
There are thirty-seven patent family members on SUN PHARM INDS INC drugs in thirteen countries and one hundred and twenty-nine supplementary protection certificates in sixteen countries.
Summary for Sun Pharm Inds Inc
| International Patents: | 37 |
| US Patents: | 11 |
| Tradenames: | 83 |
| Ingredients: | 80 |
| NDAs: | 97 |
Drugs and US Patents for Sun Pharm Inds Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | LEVULAN | aminolevulinic acid hydrochloride | SOLUTION;TOPICAL | 020965-001 | Dec 3, 1999 | RX | Yes | Yes | 11,690,914 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Sun Pharm Inds Inc | SEZABY | phenobarbital sodium | POWDER;INTRAVENOUS | 215910-001 | Nov 17, 2022 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Sun Pharm Inds Inc | GLIPIZIDE AND METFORMIN HYDROCHLORIDE | glipizide; metformin hydrochloride | TABLET;ORAL | 077620-002 | Jan 11, 2008 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Sun Pharm Inds Inc | BETHANECHOL CHLORIDE | bethanechol chloride | TABLET;ORAL | 040897-004 | Apr 22, 2009 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Sun Pharm Inds Inc | ATENOLOL | atenolol | TABLET;ORAL | 078210-003 | Jul 10, 2007 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Sun Pharm Inds Inc | ATENOLOL | atenolol | TABLET;ORAL | 078210-001 | Jul 10, 2007 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sun Pharm Inds Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-003 | May 25, 2012 | 9,078,925 | ⤷ Subscribe |
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-003 | May 25, 2012 | 8,367,102 | ⤷ Subscribe |
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-002 | May 25, 2012 | 8,367,102 | ⤷ Subscribe |
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-006 | Aug 15, 2014 | 7,435,427 | ⤷ Subscribe |
| Sun Pharm Inds Inc | ULTRAVATE | halobetasol propionate | OINTMENT;TOPICAL | 019968-001 | Dec 17, 1990 | 4,619,921 | ⤷ Subscribe |
| Sun Pharm Inds Inc | LEVULAN | aminolevulinic acid hydrochloride | SOLUTION;TOPICAL | 020965-001 | Dec 3, 1999 | 5,079,262 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SUN PHARM INDS INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 30 mg and 40 mg | ➤ Subscribe | 2012-12-31 |
| ➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2013-06-19 |
| ➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2016-05-16 |
| ➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2013-01-07 |
| ➤ Subscribe | Capsules | 35 mg | ➤ Subscribe | 2015-11-25 |
International Patents for Sun Pharm Inds Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | 112018072339 | ⤷ Subscribe |
| China | 109069493 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2017192905 | ⤷ Subscribe |
| Australia | 2020267186 | ⤷ Subscribe |
| European Patent Office | 3346996 | ⤷ Subscribe |
| Canada | 3022519 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sun Pharm Inds Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1261586 | C01261586/02 | Switzerland | ⤷ Subscribe | PRODUCT NAME: SAXAGLIPTIN UND METFORMIN; NAT. REGISTRATION NO/DATE: SWISSMEDIC 62040 20120329 |
| 1261586 | 12C0028 | France | ⤷ Subscribe | PRODUCT NAME: ASSOCIATION COMPRENANT LA SAXAGLIPTINE OU UN DE SES SELS ET LA METFORMINE OU UN DE SES SELS, Y COMPRIS L'ASSOCIATION CHLORHYDRATE DE SAXAGLIPTINE ET CHLORHYDRATE DE METFORMINE; REGISTRATION NO/DATE: EU/1/11/731/001 20111124 |
| 2498758 | PA2020003,C2498758 | Lithuania | ⤷ Subscribe | PRODUCT NAME: METFORMINO HIDROCHLORIDAS; SAKSAGLIPTINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; DAPAGLIFLOZINAS ARBA FARMACINIU POZIURIU PRIIMTINAS JO SOLVATAS; REGISTRATION NO/DATE: EU/1/19/1401 20191111 |
| 2498758 | 2090013-0 | Sweden | ⤷ Subscribe | PRODUCT NAME: A COMBINATION OF METFORMIN HYDROCHLORIDE, SAXAGLIPTIN OR A PHARMACEUTICALLY ACCEPABLE SALT THEREOF, AND DAPAGLIFLOZIN OR PH ARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF; REG. NO/DATE: EU/1/19/1401 20191113 |
| 2498758 | 132020000000034 | Italy | ⤷ Subscribe | PRODUCT NAME: METFORMINA O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE; SAXAGLIPTIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE; DAPAGLIFLOZIN O UN SUO SOLVATO FARMACEUTICAMENTE ACCETTABILE.(QTRILMET); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1401, 20191113 |
| 0502314 | C300095 | Netherlands | ⤷ Subscribe | PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
